Fogarty International Center, National Institutes of Health, 31 Center Drive, Mailstop 2220, Bethesda, MD 20892, USA.
J Infect. 2014 Jan;68 Suppl 1:S9-18. doi: 10.1016/j.jinf.2013.09.010. Epub 2013 Oct 22.
Since 2006, the availability of two new rotavirus vaccines has raised enthusiasm to consider the eventual control and elimination of severe rotavirus diarrhea through the global use of vaccines. Rotavirus remains the most severe cause of acute diarrhea in children worldwide responsible for several hundred thousands of deaths in low income countries and up to half of hospital admissions for diarrhea around the world. The new vaccines have been recommended by WHO for all infants and in more than 47 countries, their introduction into routine childhood immunization programs has led to a remarkable decline in hospital admissions and even deaths within 3 years of introduction. Challenges remain with issues of vaccine finance globally and the problem that these live oral vaccines perform less well in low income settings where they are needed most. Ongoing research that will accompany vaccine introduction might help address these issues of efficacy and new vaccines and novel financing schemes may both help make these vaccines universally available and affordable in the decade.
自 2006 年以来,两种新的轮状病毒疫苗的出现提高了人们对通过全球使用疫苗来最终控制和消除严重轮状病毒腹泻的热情。轮状病毒仍然是全球儿童急性腹泻最严重的原因,在低收入国家导致数十万人死亡,在全球范围内导致多达一半的腹泻住院治疗。世卫组织建议所有婴儿使用这两种新疫苗,在 47 个以上的国家,这些疫苗被纳入常规儿童免疫规划,在引入后的 3 年内,住院治疗甚至死亡人数显著下降。在全球疫苗融资方面仍然存在挑战,以及这些活口服疫苗在最需要的低收入环境中效果较差的问题。伴随疫苗引入的正在进行的研究可能有助于解决这些疗效问题,新疫苗和新的融资计划都可能有助于在未来十年内使这些疫苗在全球范围内普及和负担得起。